Potential Anti-Aging Effects of Psilocybin: Extending Cell Lifespan by Over 50%

Emerging research suggests that psilocybin, the compound found in magic mushrooms, may extend human cell lifespan by over 50% and support healthy aging, opening new avenues for anti-aging therapies.
Researchers are exploring the anti-aging properties of psilocybin, the active compound in psychedelic mushrooms. A recent study published in npj Aging indicates that psilocybin may significantly prolong the cellular lifespan of human skin and lung cells by over 50%. The study also suggests that psilocybin helps maintain telomere length, reduces oxidative stress, and enhances DNA repair, all of which contribute to healthier aging. Animal models demonstrated that mice given psilocybin lived longer and displayed signs of healthier aging, such as fewer white hairs and hair regrowth. While these findings are promising, experts emphasize the need for further research before considering psilocybin as a clinical anti-aging therapy. Currently known for its psychedelic effects, psilocybin's systemic health benefits could pave the way for new approaches to promote longevity and combat age-related diseases, including neurodegeneration, cardiovascular conditions, and cancer.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
The Crucial Role of Medical Professionals in Opposing the Rise of Capital Punishment
Healthcare professionals play a vital role in opposing the increasing use of the death penalty worldwide, emphasizing the ethical and human rights implications of capital punishment.
RFK Jr. Calls Off Critical US Health Panel Meeting Without Notice, Sparking Concerns
U.S. Health Secretary Kennedy unexpectedly canceled a key preventive health advisory panel meeting, raising concerns over political influence and the future of science-based health policy in the United States.
Research Links Certain Antibodies in Lupus Patients to Increased Risk of Blood Clots
A breakthrough study identifies specific antibodies in lupus patients that significantly increase their risk of blood clots, paving the way for better risk assessment and targeted treatments.



